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BACKGROUND: Fluorescence in situ hybridization (FISH) to identify specific DNA target sequences in the nuclei of nondividing
cells of numerous solid neoplasms has contributed to the introduction of molecular cytogenetics as a useful adjunct to cytology,
leading recently to the “marriage” of the 2 disciplines. Numerous cancer molecular markers can now be investigated using differ-
ent technical approaches, at both the gene and expression levels, in biopsies of various suspected cancers, including differenti-
ated thyroid carcinoma. The limited amount of bioptic material is often insufficient to carry out multiple tests, and optimizing
handling of the biopsy is desirable.METHODS: We have developed a home-brew tetracolor break-apart probe able to simul-
taneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papil-
lary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma. RESULTS: The probe had
100% specificity, 99.5% sensitivity, and 3% cutoff. The probe was tested on RET/PTC and PAX8/PPARg RT-PCR positive
controls, and feasibility was assessed in 368 thyroid nodule fine-needle aspirations (FNA). In the latter analysis, 24 FNAs
had split RET signal, and 9 had split PPARg signal. FISH analysis of available surgically removed nodules confirmed the sen-
sitivity of FISH in detecting abnormal clones and oligoclones. CONCLUSIONS: The home-brew tetracolor probe showed
high feasibility, optimizing the use of the biological material in relation to the available molecular tests and maximizing the
FISH experimental and slide-scoring times. This probe may be considered an alternative to RT-PCR when recovery and qual-
ity of RNA amplification from FNA are insufficient. Cancer (Cancer Cytopathol) 2014;000:000–000. VC 2014 The Authors.
Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access
article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and dis-
tribution in any medium, provided the original work is properly cited, the use is non- commercial and no modifications or
adaptations are made.
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INTRODUCTION
The “marriage of cytology and cytogenetics” has recently been celebrated, as reported by Dal Cin and coworkers:
“Dearly Beloved, we are gathered here to join in happy matrimony. . .Cytology and Cytogenetics?!”1 To ensure a
long-lasting marriage, it is of importance to continuously improve and innovate both the cytological side, especially
through the immunohistochemical approach,2,3 and the cytogenetic side. In this view, refining the fluorescence in
situ hybridization (FISH) probe panel suitable for targeting specific DNA regions involved in changes (such as gene
loss, amplification, gene fusion) is crucial both because of the implications for cancer research and for the efficient
use of FISH as an adjunct to cytology. Many commercially available probes are today routinely used in cytology and
histology, mainly as ancillary tools in the diagnosis of soft-tissue tumors.4 This approach is also gaining favor for
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analysis of tumors of epithelial origin5; we recently discussed
the pros and cons of FISH in papillary thyroid nodules.6
Papillary thyroid carcinoma (PTC) and follicular thyroid
carcinoma (FTC), which account for more than 80% of all
thyroid cancers, represent 2 histotypes showing definite and
distinct morphological patterns. However, in a number of
cases the morphological figure may be ambiguous and diag-
nosis not straightforward, especially in cytological prepara-
tions in which the tissue architecture of the gland is lost. In
these cases, molecular-based methodologies may be a valua-
ble adjunct. Progress in our understanding of the molecular
pathways implicated in the pathobiology of PTC and FTC
variants has revealed that several genetic changes play a mate-
rial role in the thyroid carcinogenic process. Mutations of
BRAFV600E, rearrangements of the tyrosine kinase receptor
genes RET or TRK, or mutations in RAS have been identi-
fied in approximately 70% of PTCs. Mutations of RAS or
PAX8/PPARg rearrangements have been identified in up to
75% of FTCs. The utility of molecular screening for these
markers in routine fine-needle aspiration (FNA) has been
asserted.7 It was demonstrated that more than 8% of nod-
ules with indeterminate cytological diagnosis bear genetic
alterations, including RET and PPARg rearrangements.7
Moreover, indeterminate cytology lacking the most fre-
quent genetic alterations are less likely to be malignant (6%
to 28% risk),8 indicating a benefit of the combination of
cytological evaluation and molecular analysis in the man-
agement of patients with thyroid nodules. Until recently,
the genetic alterations within and among PTC and FTC
were largely considered to be mutually exclusive.9 However,
Guerra and coworkers10 recently reported concomitant
BRAFV600E mutation and RET rearrangement in approxi-
mately 19% of the nodules studied. A rare case with a RET/
PTC rearrangement and simultaneous PAX8/PPARg rear-
rangement was also reported.11 The use of highly sensitive
methods (such as Southern blot on reverse transcriptase-
polymerase chain reaction [RT-PCR]) has been crucial in
discovering the occurrence of sporadic oligoclones with
RET rearrangements in histologically benign lesions,
whereas, the occurrence of consistent clones remains
exclusive to PTC.12 On the other hand, the meaning of
PPARg rearrangement in benign nodules is still unclear,
although studies in transgenic models suggest that lesions
carrying this anomaly may be precursors of PAX8/PPARg-
positive FTC.13 These observations have both
pathobiological and clinicopathological significance and
call for establishing precise diagnostic cutoff values. The
simultaneous investigation by FISH of the integrity of
RET and PPARg genes (indicative of RET/PTC and
PAX8/PPARg or variant fusions, respectively) would
improve thyroid FNA characterization by maximizing the
use of available biological material and would reduce the
time required for performing FISH and scoring slides.
This optimization is desirable, in part, because of the
emergence of numerous promising molecular tests that
are suited to FNA.14 Moreover, the ability to analyze
concurrently the integrity of these 2 genes would help to
identify cases with a dual mutation and would facilitate
determining their clonal relationship.
To this end, we have developed a tetracolor break-
apart cocktail probe in which 50 and 30 flanking sequences
of the RET and PPARg genes are labeled with 4 different
fluorophores. To assess the feasibility of tetracolor FISH,
the probe was tested on 368 FNA and 13 corresponding
surgically removed nodules.
MATERIALS AND METHODS
Tetracolor Break-Apart Probe Preparation
A total of 10 bacterial artificial chromosome (BAC)
clones were selected from the University of California
Santa Cruz Human Genome Browser (http://genome.
cse.ucsc.edu) and were obtained from the BACPAC
Resources Center, Children’s Hospital Oakland Research
Institute (Oakland, Calif.; http://www. chori.org/).
Selected BAC clones flanking the 50 and 30 of RET
(located at 10q11.2)6 and PPARg (located at 3p25)15 are
reported in Figure 1. The 2 proximal and 2 distal RET
BAC clones span 272.9 and 351.5 kb, respectively; the 3
proximal and 3 distal PPARg BAC clones span 609.7 and
528.4 kb, respectively (Fig. 1).
BACs were expanded, and DNA was isolated by a
HiPure Plasmid Midiprep Kit (Invitrogen, Carlsbad,
Calif.) and labeled by nick translation according to the
manufacturer’s instructions. Four different fluorophores
(Abbott Molecular/Vysis, Downers Grove, Ill) were used
to prepare the tetracolor break-apart mix: proximal and
distal RET probes were labeled with Spectrum Gold
dUTP and SpectrumGreen dUTP, respectively; proximal
and distal PPARg probes were labeled with Spectrum
Aqua dUTP and Spectrum Red dUTP, respectively,
according to the manufacturer’s instructions. The labeled
DNA from all 10 BAC clones was pooled to yield a probe
with strong FISH signals.
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Fluorescence In Situ Hybridization
The tetracolor probe was hybridized on cytogenetic and
cytological preparations using 10 lL of probe per slide
(final probe concentration 40 ng/lL). Hybridization was
performed on a HYBrite unit (Abbott Molecular/Vysis).
Denaturation was performed for 5 minutes at 75C, fol-
lowed by overnight hybridization at 37C. Posthybridiza-
tion washes were performed at 60C in 0.13 SSC 3 times
for 5 minutes. Slides were counterstained with DAPI (40,6-
diamidino-2-phenylindole dihydrochloride). Preparations
were examined on an Olympus BX41 epifluorescence
microscope equipped with a charge-coupled device camera
(Cohu, San Diego, Calif.) interfaced with the CytoVision
system (software version 3.9; Applied Imaging, Pittsburgh,
PA). Cytogenetic preparations (metaphases and nuclei)
from phytohemagglutinin-stimulated lymphocyte cultures
(in DMEM/F12 medium with additives; Gibco/Life Tech-
nologies, Milan, Italy) derived from apparently healthy
male volunteers were used to establish the analytical speci-
ficity (percentage of FISH signal located at the correct chro-
mosomal position, RET at 10q11.2 and PPARg at 3p25)
and sensitivity (percentage of metaphases or nuclei with cor-
rect FISH signal pattern) of the tetracolor probe (Fig. 2a).
Nuclei from formalin-fixed, paraffin embedded
(FFPE) tissue samples, obtained as described6 from the
apparently tumor-free contralateral lobe of 3 PTCs and 3
FTCs negative for RET/PTC and PAX8/PPARg by con-
ventional RT-PCR, were used for establishing the probe
cutoff value. This source was chosen to ensure that no
tumor tissue was present in the sample: a 30-lm section,
consecutive to the 4-lm section used for the histological
investigation, was used for nuclei isolation.
Nuclei from PTCs and FTCs positive for RET/PTC
and PAX8/PPARg alterations by conventional RT-PCR
were used to confirm the probe efficiency.
For specificity analysis, metaphases and nonoverlap-
ping nuclei with 4 visible color signals were scored. Each
fluorescence signal was singularly captured, a pseudocolor
was assigned to each, and the acquired images were super-
imposed. Merged images were edited with the Applied
CytoVision FISH program. Fifty metaphases were scored
to assess probe specificity. To establish probe sensitivity,
the metaphase findings were integrated with a scoring of
600 interphase nuclei. Signal pattern interpretation was as
follows: 2 unsplit gold/green and 2 unsplit red/aqua FISH
signals were interpreted as unbroken RET and PPARg
genes; 1 split gold/green FISH signal plus 1 unsplit gold/
green signal and 2 unsplit red/aqua FISH signals were
interpreted as 1 broken RET; and 1 split red/aqua FISH
signal plus 1 unsplit red/aqua signal and 2 unsplit gold/
green FISH signals were interpreted as 1 broken PPARg.
Figure 1. Schematic representation of the proximal and distal positions of the BAC clones used in the preparation of the gold/
green RET and red/aqua PPARg premix for the tetracolor probe setup.
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To ensure the feasibility of using a home-brew tetra-
color FISH probe in a clinical setting, the probe was tested
on 368 cytologically classified FNA samples retrieved
from our file of thyroid smears maintained at 230C. In
detail, during ultrasound-guided FNA a minimum of 5
direct smears were prepared. All smears except 1 (or more
if available) were fixed in alcohol and used for cytological
analysis. The remaining smears were air-dried, treated
with a hypotonic solution (KCl 0.075M) for 5 minutes at
37C, and fixed with methanol acetic (3:1) solution for
10 minutes at room temperature. Slides were air-dried
and checked under contrast-phase microscopy at low mag-
nification (203). The presence of approximately 150
nuclei, including both grouped (at least 5 consistent
groups) and spread, was the cutoff for eligibility. Small
nuclei, associated with lymphocytic infiltration, were not
considered. This procedure usually ensured a recovery of a
minimum of 75 nuclei with FISH signal. Thawed slides
were aged 24 hours at room temperature and, prior to
being used for FISH, were pretreated at room temperature
in acetic acid 70% (v/v) for 15 minutes, in phosphate-
buffered saline (PBS) balanced solution for 5 minutes,
and in a graded ethanol series (70%–90%–95%–100%)
for 5 minutes each. Preparations were digested with pepsin
solution (10 mg in 100 mL of 0.01 N HCl; Sigma
Aldrich, Milan, Italy) for 3 minutes at 37C, rinsed in
Figure 2. FISH with a home-brew tetracolor probe for identification of RET and PPARg breaks. (a) Specificity of the tetracolor
mix: gold/green RET gene, located at 10q11.2, and red/aqua PPARg gene, located at 3p25. (b) Nuclei of FNA (nodule 375) show-
ing broken RET: break-apart of 1 FISH gold/green signal (arrow). (c) Nuclei of FNA (nodule 265) showing broken PPARg: break-
apart of 1 FISH red/aqua signal (arrow). (d) Nuclei of a control case with both broken RET and PPARg: break-apart of 1 FISH
gold/green (yellow arrow) signal and 1 FISH red/aqua (white arrow). Nuclei and chromosomes are counterstained with DAPI.
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PBS, and dehydrated in the graded ethanol series. Of the
368 cytologically classified FNA samples, 281 have been
previously reported, and previous data were available from
an analysis of RET integrity obtained with a dual-color
FISH probe.6 According to the British Thyroid Associa-
tion, the Italian Society of Anatomic Pathology, and diag-
nostic cytology consensus, cytological diagnosis assigned
these FNA specimens to the following cytological classes:
Thy 1 (20 nodules), Thy 2 (236 nodules), Thy 3 (75 nod-
ules), Thy 4 (17 nodules), and Thy 5 (20 nodules); see
Table 1.
For each sample, a minimum of 75 and a maximum
of 300 nonoverlapping nuclei were scored. The study
was carried out in accordance with review board–
approved protocols and in compliance with the Helsinki
Declaration (http://www.wma.net/en/30publications/10
policies/b3). Written informed consent was obtained
from all patients before FNA. None of the patients of this
pilot study was advised to undergo surgery on the basis of
FISH results. Moreover, 13 samples were available for the
FISH postsurgical control study on touch preparations or
isolated nuclei from FFPE, obtained as described.6
RESULTS
Fluorescence In Situ Hybridization and Probe
Validation
The FISH analysis on lymphocytes established that the
probe exhibited 100% specificity for both RET and PPARg
and 99.5% sensitivity for RET and 99.8% for PPARg.
Taking into account the lower value, we consider the tetra-
color probe specificity to be 100% and sensitivity to be
99.5%.
To establish the cutoff value, the probe was then
tested on 1500 nuclei isolated from FFPE samples of
apparently normal thyroid tissue. The cutoff value for cor-
rectly identifying normal thyroid samples, calculated as
the beta inverse function,16 was split FISH signals in
2.4% of cells for RET and 0% for PPARg. On this basis, a
sample was considered negative for broken RET when a
split FISH signal was observed in <3% of nuclei. A sam-
ple was also considered negative for broken PPARg when a
split FISH signal was observed in <3% of nuclei (arbitra-
rily set because no broken PPARg were observed in con-
trols). Conversely, a sample was considered positive if a
broken signal for RET or PPARg was observed in 3% of
nuclei. Moreover, as already noted,6 the RET break-apart
FISH signal was observed in 3% and <6.8% of nuclei
only in single isolated scattered cells, whereas the RET
break-apart FISH signal was observed in6.8% of nuclei
among grouped nuclei.
Probe efficiency was confirmed on previously pub-
lished RT-PCR positive controls.11,17 In 1 control case of
PTC that was positive for RET/PTC1 and negative for
PAX8/PPARg, we found by FISH that 19% of nuclei had
broken RET and intact PPARg. In 1 control case of FTC
that was negative for RET/PTC and positive for PAX8/
PPARg, we found that 21% of nuclei had broken PPARg
and intact RET. In 1 control case of PTC follicular variant
positive for both RET/PTC3 and PAX8/PPARg, we con-
firmed the rearrangements of RET (in 30% of nuclei) and
PPARg (in 14% of nuclei).
Detection of RET and PPARg Rearrangement
in Cytological and Histological Samples
We found a total of 33 FNAs (9%) with broken genes, 24
with broken RET (Fig. 2b), and 9 with broken PPARg
(Fig. 2c): broken RET was observed in 9 Thy 2 (3.8%), 9
Thy 3 (12%), 1 Thy 4 (5.9%), and 5 Thy 5 (25.0%)
FNAs; broken PPARg was present in 1 Thy 1 (5%), 6 Thy
2 (2.5%), and 2 Thy 3 (2.6%) FNAs. No FNA exhibited
a dual rearrangement (Table 1) similar to the one found
in the control case (Fig. 2d).
Of 18 surgically removed nodules, 13 were available
for the FISH study. All these were RET-positive FNAs.
The surgical samples positive for PPARg unfortunately
were not available for FISH analysis. In a previous report,6
we set a 6.8% cutoff for RET clonal rearrangement, which
was associated with malignancy. In general, this threshold
was confirmed in the present series, that is, RET rear-
rangements were observed in the corresponding tumor
cells (Table 2). Moreover, these 13 samples were negative
for PPARg rearrangement, confirming the results obtained
in FNA. Of 28 surgically removed Thy 3 FISH-negative







20 Thy 1 0 1
236 Thy 2 9 6
75 Thy 3 9 2
17 Thy 4 1 0
20 Thy 5 5 0
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samples (2.6%) histology was available for 28 nodules: 21
benign and 7 malignant (2 PTC, 2 FTC, 3 PTC-follicular
variant).
DISCUSSION
Different kinds of genetic alterations, as well as epigenetic
phenomena, have been identified that are now considered
important information for classification, prognosis, and
treatment of thyroid cancer. Among commonly observed
changes are mutations, gene amplification, chromosome
translocations leading to chimeric genes, chromosome
gains, and promoter methylation.14 Consequently, con-
sidering all these features, the impact of gene alteration
testing on the diagnosis and management of patients with
thyroid cancer is increasing, particularly in view of more
accurate cancer risk stratification of lesions with an inde-
terminate presurgical diagnosis.8 Currently, several
molecular approaches are available to investigate thyroid
tumor cell pathobiology at different levels (gene, chromo-
some, gene expression). These include CGH array,18
DNA sequencing,7 polymerase chain reaction (conven-
tional, multiplex, quantitative), FISH, immunohisto-
chemistry, proteomics,19 and the recently introduced
mass spectrometry.20 The integration of results obtained
by these technologies has been invaluable in clarifying
genetic alterations associated with thyroid cancer and in
interpreting the key roles of impaired signaling pathways.
One of the main aspects highlighted by the molecular
studies is the presence of intratumoral heterogeneity in
the distribution of the genetic changes,21 for example, a
mixture of cells with and without rearrangements. This
finding may dispute the tumorigenic role attributed to the
most common thyroid carcinoma–related mutations,
Table 2. FISH Results on Cytological and Histological Preparations Using the Tetracolor Break-Apart Probe
Nodule ID
FNA Tissue
Cytology FISH Broken RET FISH Broken PPARg Histology FISH Broken RET
532 Thy 1 neg pos Adm goiter NA
1 Thy 2 posOC neg No surgery
16 Thy 2 posOC neg No surgery
20 Thy 2 posOC neg FTA neg
34 Thy 2 neg pos No surgery
40 Thy 2 posOC neg No surgery
80 Thy 2 neg pos No surgery
169 Thy 2 neg pos No surgery
334 Thy 2 posOC neg No surgery
294 Thy 2 posC neg No surgery
362 Thy 2 posOC neg No surgery
380 Thy 2 neg pos No surgery
411 Thy 2 neg pos No surgery
490 Thy 2 posOC neg No surgery
519 Thy 2 posOC neg No surgery
535 Thy 2 neg pos No surgery
9 Thy 3 posOC neg Benign neg
26 Thy 3 posOC neg PTC-FVa neg
32 Thy 3 posOC neg No surgery
36 Thy 3 posOC neg Benigna neg
82 Thy 3 posOC neg Benign neg
265 Thy 3 neg pos PTC-FV NA
323 Thy 3 posOC neg Benign neg
375 Thy 3 posOC neg microPTC posC
413 Thy 3 neg pos Adm goiter NA
488 Thy 3 posOC neg Mltn goiter NA
542 Thy 3 posOC neg PTC-FV NA
60 Thy 4 posC neg PTC posC
13 Thy 5 posOC neg PTC-WLV neg
228 Thy 5 posC neg PTC posC
260 Thy 5 posC neg PTC posC
284 Thy 5 posC neg PTC posC
295 Thy 5 posOC neg PTC neg
Adm goiter, adenomatous goiter; FTA, follicular thyroid adenoma; NA, not available; pos, positive, break 3%, no threshold set for PPARg clonal change (see
discussion); posC, positive, clonal change (break 6,8%); posOC, positive, oligoclonal change (break 3% and <6,8%); PTC, papillary thyroid carcinoma;
PTC-FV, PTC–follicular variant; Mltn goiter, multinodular goiter; PTC-WLV, PTC–Whartin-like variant.
a Lesion with occult PTC; number of patients 5 368.
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confining them to a secondary role in tumor initiation but
possibly maintaining a key role in the final diagnosis, with
clinical and treatment implications.22 In fact, the biologi-
cal and clinical meaning of finding or not finding multiple
changes in the same or separate clones might be different,
especially if such heterogeneity affects morphological
aspects. As the presence of dual mutations in the same
nodule is an emerging finding, understanding the recipro-
cal role of concurrent impaired genes that are involved in
the same or different signaling pathways is challenging.10
Among the above-mentioned techniques, only FISH ena-
bles identifying gene fusion within a single nucleus and
permits localizing chimeric genes within the same cell or
in different cells. In this regard, the probe we have devel-
oped has an added value, allowing determination of the
prevalence of simultaneous RET and PPARg rearrange-
ments in differentiated thyroid cancer variants. In the
present series, we found 33 cases with RET or PPARg rear-
rangement. PPARg rearrangement was found in Thy
1-Thy 3 classes but not in Thy 4 or Thy 5. Absence of
PPARg rearrangement in Thy 5 cases is expected because
PTCs are usually found in this class.
We recently reported the importance of FISH as an
adjunct to cytology in thyroid nodule management, high-
lighting the challenge associated with interpretation of
results and the need for precise laboratory FISH cutoffs.6
Interpretation of FISH results (far from being “counting
dots”) can be rather complex, and the pathologist and the
cytogeneticist should work in concert to reach a conclu-
sive result. It is a fact that oligoclonal foci of molecularly
abnormal epithelial cells without morphologic abnormal-
ities can be detected throughout the thyroid epithelium,
and the finding of isolated single sporadic FISH RET-pos-
itive cells in FNAmight reflect this pattern. Accumulating
knowledge on the prevalence of RET and PPARg rear-
rangements in thyroid nodules would lead to a better
understanding not only of the follicular cell carcinoge-
netic process but also of the diagnostic and prognostic
potential of these markers. The clinical implication of
RET activation in sporadic cells is still debated, and it is
not known if a phenomenon of field cancerization23 and a
different capability of individual cells to respond to
growth-regulating signals from neighboring cells are
responsible for the expansion of a “cell patch” with RET
rearrangement. Nevertheless, although considered fully
benign, careful follow-up is indicated for FNA with
benign classification (Thy 2) and RET rearrangement
ascertained by Southern blot on RT-PCR because they
grow rapidly.12 According to Marotta et al,12 FISH is, at
present, the most appropriate method for detecting clonal
changes with a view toward refining indeterminate cytol-
ogy. In our view,6 FNA containing grouped cells with an
identical abnormal FISH pattern is indicative of an appre-
ciable clonal growth, whereas sporadic cells with the same
abnormal pattern possibly indicate an oligoclonal process.
Translating FISH analysis of thyroid FNA into the clini-
cal setting will be a future step; at the moment, the Inter-
national System for Human Cytogenetic Nomenclature24
does not contain definitions dedicated to FISH results for
clones, oligoclones, clonal evolution, and unrelated
clones. In the present series, excluding nodule 375, with a
histological diagnosis of microcarcinoma and sporadic
change (possibly from FNA bias), 71% of Thy 3 nodules
with RET-positive scattered cells proved to be benign,
confirming the appropriateness of a 6.8% cutoff for
malignancy. Because of the unavailability of surgical
material for FISH, any effort to correlate the presence of
sporadic cells with PPARg rearrangement and the final
diagnosis was impaired. Nevertheless, we would point out
that a Thy 3 cytological sample with broken PPARg in
16% of nuclei had a diagnosis of follicular variant of
PTC, a variant often exhibiting this anomaly. Further
study will be needed to confirm the hypothesis that
PPARg rearrangements may be precursors of PPARg-rear-
ranged positive FTC, as suggested by analysis of a trans-
genic mouse model.13 Our findings indicate the feasibility
of optimizing molecular cytogenetics in presurgical thy-
roid material, improving and supporting the use of FISH
as an adjunct to cytology. Early cytogenetic studies have
characterized different cytogenetic subclasses of differenti-
ated thyroid tumors.25 FISH analysis revealed a higher
rate of thyroid tumors with clonal cytogenetic deviations
than conventional cytogenetics.26 Rapidly increasing the
use of molecular approaches for analyzing FNA material
is occurring,7,14 especially in the effort to better character-
ize nodules with indeterminate cytological diagnosis.8
Although the management of approximately 30% of thy-
roid cancers remains problematic because they do not
show common mutations detectable by the currently
available molecular tests,27 molecular tests may be inform-
ative in most nodules with indeterminate cytology. The
use of ancillary techniques on direct-smear aspirates repre-
sents a significant evolution for cytopathologic techni-
ques.28 Data correlating clonal/oligoclonal expansion of
Tetracolor FISH for RET and PPARg/Caria et al
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gene-rearranged cells with clinical outcomes in thyroid
neoplasms need to be explored and improved because
both RET/PTC and PAX8/PPARg protein products are
attractive diagnostic targets.29,30 FNA provides a unique
chance for presurgical diagnosis of a thyroid nodule.
Assessing the presence of the corresponding chimeric
genes in presurgical samples is becoming unavoidable.
RT-PCR is a good routine methodology for this purpose;
however, recovery and quality of RNA amplification from
FNA may be a limiting factor. In this case, the tetracolor
probe may overcome this limitation, although further
studies are needed to ascertain whether and to what extent
FISH technology may improve the diagnostic accuracy of
indeterminate (Thy 3) cytology. As for other tumors1
such as renal tumors,31 the application of FISH to FNA
has been reported to be significant for tumor subclassifica-
tion. In this regard, collecting as much information as
possible on the status of RET and PPARg in thyroid FNA
and comparing the data with the morphological patterns
and clinical outcomes would provide a deeper and more
focused understanding of the diagnostic and prognostic
value of these rearrangements in thyroid lesions.
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